登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07103395,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Patients must have histologically or cytologically confirmed locally advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC);
入选标准第 2 条
Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days [one ovulation cycle] plus approximately five half-lives of the study drug);
入选标准第 8 条
History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;
排除标准第 12 条
Current or prior use of immunosuppressive medication within 28 days before the first dose of Iparomlimab and tuvonralimab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.
排除标准第 28 条
Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy will be excluded from randomization;
排除标准第 29 条
Patients with Grade ≥2 pneumonitis from prior chemoradiation therapy will be excluded from randomization;
排除标准第 30 条
Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE>Grade 1.
排除标准第 31 条
WHO Performance Status (PS) score of 0 or 1;
入选标准第 6 条
World Health Organization (WHO) Performance Status of 2-4;
排除标准第 17 条
EGFR, ALK, and ROS1 wild-type;
入选标准第 3 条
Absolute neutrophil count ≥ 1.5 × 10⁹/L;
入选标准第 11 条
Platelets ≥ 100 × 10⁹/L;
入选标准第 12 条
Hemoglobin ≥ 9.0 g/dL;
入选标准第 13 条
Creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976);
入选标准第 14 条
Serum bilirubin ≤ 1.5 × upper limit of normal (ULN);
入选标准第 15 条
AST and ALT ≤ 2.5 × ULN.
入选标准第 16 条
Absolute neutrophil count <1.5 x 109/L (1500 per mm3)
排除标准第 20 条
Platelets <100 x 109/L (100,000 per mm3)
排除标准第 21 条
Haemoglobin<9.0 g/dL (5.59 mmol/L)
排除标准第 22 条
Serum creatinine CL <50 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976)
排除标准第 23 条
Serum bilirubin >1.5 x upper limit of normal (ULN).
排除标准第 24 条
Aspartate Transaminase(AST) and Alanine Transaminase(ALT) >2.5 x ULN.
排除标准第 25 条
Mixed small cell and non-small cell lung cancer histology;
排除标准第 3 条
Female subjects must not be breastfeeding;
入选标准第 7 条
Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07103395,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Males or females aged 18 to 75 years or older; Patients must have histologically or cytologically confirmed locally advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC); EGFR, ALK, and ROS1 wild-type; No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy; Expected survival ≥ 12 weeks; WHO Performance Status (PS) score of 0 or 1; Female subjects must not be breastfeeding; Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days [one ovulation cycle] plus approximately five half-lives of the study drug); Adequate organ and bone marrow function as defined by the following criteria: Forced Expiratory Volume in 1 second (FEV1) ≥ 800 mL; Absolute neutrophil count ≥ 1.5 × 10⁹/L; Platelets ≥ 100 × 10⁹/L; Hemoglobin ≥ 9.0 g/dL; Creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Serum bilirubin ≤ 1.5 × upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN.排除标准:Exclusion Criteria:
Exclusion criteria for enrolment for neoadjuvant therapy. Patients should not enter the study if any of the following exclusion criteria are fulfilled: Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study; Mixed small cell and non-small cell lung cancer histology; Prior use of anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies; Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access; Active or prior documented autoimmune disease within the past 2 years; Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis); History of primary immunodeficiency; History of organ transplant that requires therapeutic immunosuppression; Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent; Known history of tuberculosis; History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study; Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control. Exclusion criteria for concurrent chemoradiation following neoadjuvant therapy. Patients should not enter the concurrent chemoradiation phase if any of the following exclusion criteria are fulfilled: Patients who develop distant metastasis; Patients who develop locoregional disease progression and the irradiation dose of normal tissue will exceed the limit. World Health Organization (WHO) Performance Status of 2-4; Inadequate organ and marrow function as defined below: Forced expiratory volume in 1 second (FEV1) <800ml Absolute neutrophil count <1.5 x 109/L (1500 per mm3) Platelets <100 x 109/L (100,000 per mm3) Haemoglobin<9.0 g/dL (5.59 mmol/L) Serum creatinine CL <50 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) Serum bilirubin >1.5 x upper limit of normal (ULN). Aspartate Transaminase(AST) and Alanine Transaminase(ALT) >2.5 x ULN. Further exclusion criteria for consolidation therapy. Patients should not enter the consolidation therapy if any of the following exclusion criteria are fulfilled: Patients who have progressed whilst definitive platinum based, concurrent chemoradiation therapy; Current or prior use of immunosuppressive medication within 28 days before the first dose of Iparomlimab and tuvonralimab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed. Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy will be excluded from randomization; Patients with Grade ≥2 pneumonitis from prior chemoradiation therapy will be excluded from randomization; Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE>Grade 1.
引自 ClinicalTrials.gov, NCT07103395, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07103395,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。